Generated by AI
KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare and severe diseases of the eye. KALA BIO’s current work centers on biologics-based investigational treatments built on its proprietary mesenchymal stem cell secretome platform, with KPI-012 as its lead product candidate for persistent corneal epithelial defects and other corneal disorders. The company also evaluates the platform for broader ophthalmic applications, including limbal stem cell deficiency and retinal degenerative diseases. KALA BIO serves the biotechnology and pharmaceutical research space through its development pipeline and commercialization efforts, with an emphasis on unmet medical needs in eye health. Headquartered in Arlington, Massachusetts, KALA BIO operates as a specialized participant in the ophthalmology and biotechnology markets.
Website1167 Massachusetts Avenue
Arlington, MA, 02476
United States
The latest articles about KALA.
Common Stock Will Begin Trading on a Split-Adjusted Basis on November 16, 2026Arlington, Massachusetts--(Newsfile Corp. - November 12, 2026) - KALA BIO, Inc. (NASDAQ: KALA) ("KALA BIO" or the "Company"), today announced that it intends to effect a reverse stock split of its common stock, par value $0.001 per share (the "common stock"), at a ratio of 1 post-split share for every 30 pre-split shares. The reverse stock split will become effective at 4:05 p.m. on Friday, November 13, 2026. The...
Summary of Nov 16's posts. Generated by AI.
Summary of Sep 30's posts. Generated by AI.
FingerMotion jumped 18.1% premarket after agreeing to buy Newbit Technology for $2.3M cash; NewGenIvf led gainers at 187.2%, while Silexion fell 16.6%.
Summary of Nov 16's posts. Generated by AI.
Investors talking about KALA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.